Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADDXFNASDAQ:AZRXNASDAQ:LIXTNYSE:NBYOTCMKTS:NWPHF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AAZRXAzurRx BioPharma$0.40-0.5%$4.04$3.36▼$26.30$3.76M1.51628,703 shs68,057 shsLIXTLixte Biotechnology$2.63+30.1%$1.24$0.64▼$4.25$7.05M0.31648,227 shs64.13 million shsNBYNovaBay Pharmaceuticals$0.63+0.6%$0.59$0.36▼$2.45$3.66M0.43122,618 shs8,792 shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%AZRXAzurRx BioPharma+3.71%-12.36%-8.00%-7.32%-58.68%LIXTLixte Biotechnology+30.15%+241.43%+86.45%+117.27%+13.32%NBYNovaBay Pharmaceuticals+0.62%+4.83%+12.89%+21.71%-71.01%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%-22.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ALIXTLixte Biotechnology0.936 of 5 stars0.05.00.00.02.30.80.0NBYNovaBay Pharmaceuticals2.0711 of 5 stars3.50.00.00.00.01.71.3NWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex Therapeutics 0.00N/AN/AN/AAZRXAzurRx BioPharma 0.00N/AN/AN/ALIXTLixte Biotechnology 0.00N/AN/AN/ANBYNovaBay Pharmaceuticals 3.00Buy$0.8535.14% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A($1.19) per shareN/ANBYNovaBay Pharmaceuticals$9.78M0.37N/AN/A$4.25 per share0.15NWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/ALIXTLixte Biotechnology-$3.59M-$1.45N/A∞N/AN/AN/A-189.35%8/6/2025 (Estimated)NBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ANWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/ALatest LIXT, AZRX, NBY, ADDXF, and NWPHF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/AAZRXAzurRx BioPharmaN/A1.331.33LIXTLixte BiotechnologyN/A4.264.26NBYNovaBay PharmaceuticalsN/A1.150.91NWPHFNewron PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AAZRXAzurRx BioPharma6.27%LIXTLixte Biotechnology5.10%NBYNovaBay Pharmaceuticals23.25%NWPHFNewron PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AAZRXAzurRx BioPharma7.30%LIXTLixte Biotechnology14.80%NBYNovaBay Pharmaceuticals0.10%NWPHFNewron PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableLIXTLixte Biotechnology42.68 million2.29 millionNot OptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableLIXT, AZRX, NBY, ADDXF, and NWPHF HeadlinesRecent News About These CompaniesNewron Pharmaceuticals S.p.A. Just Missed EPS By 53%: Here's What Analysts Think Will Happen NextApril 5, 2025 | finance.yahoo.comEQS-News: Newron presents 2024 financial results and provides 2025 outlookApril 1, 2025 | markets.businessinsider.comNewron Pharmaceuticals S.p.A.: Newron Presents 2024 Financial Results and Provides 2025 OutlookApril 1, 2025 | finanznachrichten.deNewron Presents 2024 Financial Results and Provides 2025 OutlookApril 1, 2025 | finance.yahoo.comNewron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent ChairmanMarch 24, 2025 | uk.finance.yahoo.comEQS-News: Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent ChairmanMarch 24, 2025 | markets.businessinsider.comThose who invested in Newron Pharmaceuticals (VTX:NWRN) three years ago are up 548%March 17, 2025 | finance.yahoo.comNewron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH ConferenceMarch 11, 2025 | businesswire.comNewron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South KoreaJanuary 11, 2025 | pharmabiz.comPNewron and Myung In Pharm announce license agreement for schizophrenia therapy in South KoreaJanuary 10, 2025 | financialexpress.comFNewron and Myung In Pharm sign agreement for evenamide developmentJanuary 10, 2025 | pharmaceutical-technology.comPEQS-News: Newron and Myung In Pharm announce license agreement for evenamide in South KoreaJanuary 9, 2025 | markets.businessinsider.comNewron out-licenses evenamide in South KoreaJanuary 9, 2025 | thepharmaletter.comTNewron and Myung In Pharm Announce License Agreement for evenamide in South KoreaJanuary 9, 2025 | finance.yahoo.comEvenamide by Newron Pharmaceuticals for Schizophrenia: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPNewron stock soars on €117M EA Pharma deal for schizophrenia drugDecember 17, 2024 | bioworld.comBNewron out-licenses evenamide to Eisai unit EA PharmaDecember 13, 2024 | thepharmaletter.comTNewron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian TerritoriesDecember 13, 2024 | finance.yahoo.comEisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-onDecember 13, 2024 | fiercebiotech.comFEQS-News: Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territoriesDecember 13, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIXT, AZRX, NBY, ADDXF, and NWPHF Company DescriptionsAddex Therapeutics OTCMKTS:ADDXF$0.99 0.00 (0.00%) As of 02/3/2023Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.AzurRx BioPharma NASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Lixte Biotechnology NASDAQ:LIXT$2.63 +0.61 (+30.15%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$2.38 -0.25 (-9.66%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.NovaBay Pharmaceuticals NYSE:NBY$0.63 +0.00 (+0.62%) As of 07/3/2025 03:30 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 06/27/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
